Penumbra, Inc.

NYSE:PEN Stock Report

Market Cap: US$11.6b

Penumbra Past Earnings Performance

Past criteria checks 1/6

Penumbra has been growing earnings at an average annual rate of 33.8%, while the Medical Equipment industry saw earnings growing at 15.1% annually. Revenues have been growing at an average rate of 17.6% per year. Penumbra's return on equity is 3.5%, and it has net margins of 3.4%.

Key information

33.8%

Earnings growth rate

32.2%

EPS growth rate

Medical Equipment Industry Growth8.9%
Revenue growth rate17.6%
Return on equity3.5%
Net Margin3.4%
Last Earnings Update31 Mar 2025

Recent past performance updates

Recent updates

Earnings Beat: Penumbra, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Apr 26
Earnings Beat: Penumbra, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Penumbra Off And Running On Renewed Enthusiasm For Mechanical Thrombectomy

Mar 13

Penumbra (NYSE:PEN) Will Be Hoping To Turn Its Returns On Capital Around

Jan 27
Penumbra (NYSE:PEN) Will Be Hoping To Turn Its Returns On Capital Around

Penumbra: Re-Rated For The Wrong Reasons

Jan 07

Investors Appear Satisfied With Penumbra, Inc.'s (NYSE:PEN) Prospects

Dec 31
Investors Appear Satisfied With Penumbra, Inc.'s (NYSE:PEN) Prospects

Penumbra (NYSE:PEN) May Have Issues Allocating Its Capital

Oct 06
Penumbra (NYSE:PEN) May Have Issues Allocating Its Capital
author-image

CAVT Technology Powers Thrombectomy Leader To Transformative Growth And Global Expansion

Aug 27 Introduction of CAVT technology positions Penumbra as a thrombectomy leader, driving revenue growth through innovation and market share gains.

Penumbra Grinding Through A Painful Growth Expectations Reset

Aug 20

What You Can Learn From Penumbra, Inc.'s (NYSE:PEN) P/S

Aug 01
What You Can Learn From Penumbra, Inc.'s (NYSE:PEN) P/S

Penumbra, Inc. (NYSE:PEN) Shares Could Be 23% Above Their Intrinsic Value Estimate

Jul 11
Penumbra, Inc. (NYSE:PEN) Shares Could Be 23% Above Their Intrinsic Value Estimate

Returns At Penumbra (NYSE:PEN) Appear To Be Weighed Down

Jun 19
Returns At Penumbra (NYSE:PEN) Appear To Be Weighed Down

Penumbra: Appeal Improves As Operating Leverage Continues

May 30

Penumbra: Appeal Improves, Just Not Appealing Yet

Oct 16

Penumbra: Consolidation Does Nothing To Change Long-Term Thesis, Reiterate Buy

Sep 01

Penumbra: Future Upside Drivers In Fundamental, Sentimental And Valuation Factors

Jun 22

Penumbra Non-GAAP EPS of $0.16 beats by $0.01, revenue of $221.22M beats by $4.19M

Feb 23

Revenue & Expenses Breakdown

How Penumbra makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NYSE:PEN Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 251,2404258392
31 Dec 241,1951457495
30 Sep 241,1643555697
30 Jun 241,1341453792
31 Mar 241,0969352889
31 Dec 231,0599150684
30 Sep 239954149280
30 Jun 239382947581
31 Mar 23885646279
31 Dec 22847-245079
30 Sep 22830-3143981
30 Jun 22806-1942576
31 Mar 22782-640174
31 Dec 217485378105
30 Sep 217103437681
30 Jun 216711635890
31 Mar 21592-532793
31 Dec 20560-1628788
30 Sep 20539-1028572
30 Jun 205271127860
31 Mar 205563928653
31 Dec 195474827352
30 Sep 195234525950
30 Jun 194951524545
31 Mar 194711223240
31 Dec 18445722636
30 Sep 18420921634
30 Jun 183922820733
31 Mar 183631319633
31 Dec 17334518432
30 Sep 17311-717429
30 Jun 17294516628
31 Mar 17279915826
31 Dec 162631514824
30 Sep 162451813623
30 Jun 16228612521
31 Mar 16205311520
31 Dec 15186110218
30 Sep 1516709217
30 Jun 15149-18216
31 Mar 15138-17215
31 Dec 14126-16416

Quality Earnings: PEN has a large one-off loss of $110.3M impacting its last 12 months of financial results to 31st March, 2025.

Growing Profit Margin: PEN's current net profit margins (3.4%) are lower than last year (8.5%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: PEN's earnings have grown significantly by 33.8% per year over the past 5 years.

Accelerating Growth: PEN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: PEN had negative earnings growth (-54.8%) over the past year, making it difficult to compare to the Medical Equipment industry average (8.5%).

Return on Equity

High ROE: PEN's Return on Equity (3.5%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/28 01:44
End of Day Share Price 2025/04/28 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Penumbra, Inc. is covered by 26 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David RescottBaird
null nullBaird
Ishan MajumdarBaptista Research